James Lind Alliance

James Lind Alliance The James Lind Alliance brings together patients, carers, and clinicians to identify and prioritize outstanding uncertainties about treatments, aiming to align National Health Service research with public priorities. It originated from concerns voiced by organizations such as the National Institute for Health and Care Excellence, Medical Research Council, and Wellcome Trust about research agendas set by funders like UK Research and Innovation and European Commission programmes. The initiative interfaces with bodies including National Institute for Health Research, National Institute for Health and Care Excellence, British Medical Association, Royal College of Physicians, and patient groups such as National Voices and Cancer Research UK affiliates.

History and founding

The concept traces inspiration to the 18th-century physician James Lind and his Treatise of the Scurvy experiments alongside contemporaries linked to Royal Navy voyages and East India Company expeditions. Modern formation involved stakeholders from University of Oxford research units, the University of Aberdeen clinical trial community, and policy actors from Department of Health and Social Care in the early 2000s. Key events include consultations with the Medical Research Council, dialogues at Wellcome Trust workshops, and commissioning by National Institute for Health Research to pilot collaborative priority-setting with charities such as British Heart Foundation, Versus Arthritis, Alzheimer's Society, and Macmillan Cancer Support. Founders engaged figures from Cochrane Collaboration, the King's Fund, and consumer groups like Which? to design methods that diverged from traditional agendas set by funders such as European Commission Horizon 2020 consortia.

Structure and governance

Operational oversight is provided by a coordinating centre historically hosted within academic institutions similar to departments at University of Southampton and linked to research infrastructure like Clinical Trials Unit networks and the National Institute for Health Research Clinical Research Network. Governance incorporates representation from charities including Royal College of Nursing, professional bodies such as Royal College of Surgeons of England, regulatory stakeholders like Medicines and Healthcare products Regulatory Agency, and patient umbrella groups such as Healthwatch England. Advisory roles draw on expertise from Cochrane, Centre for Evidence-Based Medicine, and international partners like World Health Organization collaborating networks. Financial support has come from funders including Wellcome Trust, Guy's and St Thomas' Charity, and foundation donors such as Wellcome Trust and philanthropic trusts associated with institutions like King's College London.

Priority-setting partnerships and process

Priority-setting Partnerships (PSPs) convene patients, carers, and clinicians from disease-focused communities including Diabetes UK, Cancer Research UK, Stroke Association, Asthma UK, Parkinson's UK, and Multiple Sclerosis Society, and clinical specialties represented by Royal College of General Practitioners, Royal College of Paediatrics and Child Health, Royal College of Obstetricians and Gynaecologists, Royal College of Emergency Medicine, and Faculty of Pain Medicine. The process adapts methods from Cochrane Collaboration systematic review standards and incorporates survey tools used by National Cancer Research Institute and data sources like ClinicalTrials.gov and the European Medicines Agency registries to verify uncertainties. PSP stages—scope setting, question collection, evidence checking, interim prioritisation, and final consensus workshop—often employ consensus techniques akin to those in Delphi method studies used by the National Institutes of Health and panels involving representatives from NHS England trusts and academic centres such as Imperial College London and University College London.

Impact and outcomes

PSPs have produced top-ten research priorities in areas including Type 1 diabetes, asthma, Dementia, depression, Stroke, Chronic pain, Endometriosis, Parkinson's disease, Sepsis, and Paediatric oncology. These priorities have influenced funding from bodies like National Institute for Health Research, Medical Research Council, Wellcome Trust, and charitable funders such as British Heart Foundation and Versus Arthritis, and shaped calls within programmes run by European Commission Horizon Europe and international funders like Bill & Melinda Gates Foundation. Outcomes include commissioning of clinical trials at University of Oxford, University of Edinburgh, and University of Bristol clinical trial units, systematic reviews by Cochrane, and patient-involved research funded via Health Technology Assessment programme mechanisms. Impact assessments have been cited in policy documents from Department of Health and Social Care and reports to House of Commons committees.

Criticisms and limitations

Critiques have been raised by academics and commentators from institutions such as London School of Hygiene & Tropical Medicine, Nuffield Trust, and think tanks like The King's Fund regarding representativeness of participants from underserved regions including communities served by NHS Scotland or Health and Social Care Northern Ireland. Methodological concerns reference limits noted in literature from BMJ, The Lancet, and JAMA about survey bias, online digital exclusion affecting responses from groups represented by Age UK and Mencap, and challenges aligning PSP priorities with mechanistic research funded by agencies like European Research Council and translational programmes at National Institute for Health Research. Additional limitations include resource constraints reported by charities such as Macmillan Cancer Support and operational dependence on coordinating centres at universities, leading to variability highlighted by reviews published in journals associated with Oxford University Press and critiques in forums convened by Royal Society and professional conferences like Association of Medical Research Charities meetings.

Category:Medical research organizations